AIDS Therapies

SDF-1-Derived Peptides Can Be Modified Without Side Effects

Published in AIDS Weekly, August 6th, 2001

by Michael Greer, senior medical writer - Some peptides derived from stromal cell-derived factor 1 (SDF-1) can be modified to enhance their viral inhibiting abilities without affecting their impact on healthy cells, researchers in France report.

"Small compounds capable of blocking the [SDF-1] receptor CXCR4 may be potentially useful as anti-inflammatory, antiallergic, immunomodulatory, and antihuman immunodeficiency virus (HIV) agents," explained Stefano Marullo and colleagues at Cochin Hospital in Paris and other institutions.

Substituted SDF-1-based compounds can be developed that have an improved ability to compete with HIV for the CXCR4...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2001-08-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry